ALLIANCE Mitral: Safety and Effectiveness of SAPIEN X4 Transcatheter Heart Valve - Mitral
← catalyst calendarNCT06167213 · readout ≤ 955 d
Sponsored by Edwards Lifesciences (industry) · EW — their whole pipeline →.
Phase
Not applicable
Status
Not yet recruiting
Study type
Interventional
Design
Non randomized · None · Treatment
Enrollment
125estimated
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | Jan 2027 | estimated | When the study began enrolling |
| Primary completion | Mar 2029 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Mar 2038 | estimated | The whole study's end, after follow-up |
| First posted | 2023-12-12 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2025-12-22 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Mitral Regurgitation
- Mitral Valve Disease
- Mitral Stenosis
Intervention
- Device: SAPIEN X4 THV
Primary outcome
what the primary-completion date above is the date OFNon-hierarchical composite of death and stroke at 1 year
measured 1 year
Permalink · EW's whole pipeline · Catalyst calendar · Every registered study · What changed